Xiaotian Michelle Zhang

Treatment with <scp>LY</scp> 2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes

Cristina B. Guzmán, Xiaotian Michelle Zhang, Rong Liu et al. · Diabetes Obesity and Metabolism · 2017 · 165 citations

Medicine, Endocrinology, Pharmacology +17

Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real‐world setting

Elizabeth R. Seaquist, Hélène Dulude, Xiaotian Michelle Zhang et al. · Diabetes Obesity and Metabolism · 2018 · 54 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +17

A phase 3 multicenter, open-label, prospective study designed to evaluate the effectiveness and ease of use of nasal glucagon in the treatment of moderate and severe hypoglycemia in children and adolescents with type 1 diabetes in the home or school setti

Larry C. Deeb, Hélène Dulude, Cristina B. Guzmán et al. · Pediatric Diabetes · 2018 · 50 citations · Full text

Medicine, Endocrinology, Pediatrics +17

Coding variants in PNPLA3 and TM6SF2 are risk factors for hepatic steatosis and elevated serum alanine aminotransferases caused by a glucagon receptor antagonist

Cristina B. Guzmán, Suman Duvvuru, P. Anthony Akkari et al. · Hepatology Communications · 2018 · 18 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison

Emily R. Hankosky, Xuanyao He, Raleigh Malik et al. · Diabetes Obesity and Metabolism · 2025 · 15 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17